ADHD Medication and Cardiovascular Risk

Plain-language summary

Research suggests that while ADHD medications can be very helpful, it's important to be aware of potential cardiovascular effects. While some studies show very small risks, others highlight the need for careful monitoring, especially in certain populations. The overall evidence indicates that these risks are generally low for most people but careful consideration of individual patient health is always recommended.

Key findings

• A comprehensive review indicated a slightly increased risk of cardiovascular diseases associated with ADHD medications, but this risk is generally small.
• Specific studies are needed to further understand the long-term cardiovascular safety of ADHD medications in people with pre-existing conditions like schizophrenia spectrum disorders.
• Some research points to the need for continued monitoring of cardiovascular side effects linked to ADHD medication use, particularly through global pharmacovigilance efforts.

Studies cited (8)

1. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis — Zhang L, Yao H, Li L (2022, JAMA network open, meta-analysis)

   DOI: 10.1001/jamanetworkopen.2022.43597 PMCID: PMC9685490

2. Long term safety of ADHD medication in patients with schizophrenia spectrum disorders — Luykx JJ, Corbeil O, Kärkkäinen O (2025, Molecular psychiatry, other)

   DOI: 10.1038/s41380-025-03080-3 PMCID: PMC12436181

3. Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 — GBD Epilepsy Collaborators (2025, The Lancet. Public health, other)

   DOI: 10.1016/S2468-2667(24)00302-5 PMCID: PMC11876103

4. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 — GBD 2021 Causes of Death Collaborators (2024, Lancet (London, England), other)

   DOI: 10.1016/S0140-6736(24)00367-2 PMCID: PMC11126520

5. Global burden of ADHD medication-associated cardiovascular disease, 1967-2023: A comparative analysis using the WHO pharmacovigilance database — Cho H, Lee K, Jeong YD (2024, Asian journal of psychiatry, other)

   DOI: 10.1016/j.ajp.2024.104209

6. Methylphenidate and Short-Term Cardiovascular Risk — Garcia-Argibay M, Bürkner PC, Lichtenstein P (2024, JAMA network open, other)

   DOI: 10.1001/jamanetworkopen.2024.1349 PMCID: PMC10918505

7. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study — Man KKC, Häge A, Banaschewski T (2023, The lancet. Psychiatry, other)

   DOI: 10.1016/S2215-0366(23)00042-1

8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY — Garvey WT, Mechanick JI, Brett EM (2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, other)

   DOI: 10.4158/EP161365.GL